adagrasib

AssetAlso called Krazati, MRTX849

Inhibits mutant KRAS G12C, blocking signaling that drives tumor growth.

Stage
Approved
Modality
Small molecule
Target
KRAS
17
Indications
29
Trials
1
Developer

Approved by the FDA on Dec 12, 2022 (NDA216340). 2 approvals stand. FDA

Indications

17
  • Non-small cell lung cancer

    Approved, FDA

  • Advanced non small cell lung cancer

    Approved, EMA

  • Locally advanced or metastatic colorectal cancer with KRAS G12C mutation

    Approved, FDA

14 more

In the full profile

  • Target and mechanism1
  • Owner and partners2
  • Trials29
  • Evidence for its targets1
  • Competitors12
  • Signals11

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets